Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Alfresa HoldingsALFRY 75 Receivables Turnover is 1.03 as of Mar. 2026. GuruFocus rates ALFRY with a GF Score™ of 75/100 and a GF Value™ of $16.24 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 116 Medical Distribution companies, Alfresa Holdings ranks worse than 53.45% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Alfresa Holdings's Revenue for the
three
months ended in Mar. 2026 was $4,670 Mil. Alfresa Holdings's average Accounts Receivable for the
three
months ended in Mar. 2026 was $4,555 Mil.
Hence, Alfresa Holdings's Receivables Turnover for the
three
months ended in Mar. 2026 was 1.03.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Alfresa Holdings Receivables Turnover Related Terms
Alfresa Holdings Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Alfresa Holdings's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ALFRY vs MCK, CAH, COR: Receivables Turnover Comparison
For the Medical Distribution subindustry, Alfresa Holdings's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alfresa Holdings Receivables Turnover vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Alfresa Holdings's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Alfresa Holdings's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alfresa Holdings (ALFRY) has a Receivables Turnover of 1.03 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Alfresa Holdings and its competitors. According to the industry distribution chart, Alfresa Holdings ranks #62 out of 116 companies in the Medical Distribution industry, placing it in the top 53.4%.
Is Alfresa Holdings' Receivables Turnover too high?
Alfresa Holdings' current Receivables Turnover is 1.03. The Medical Distribution industry median Receivables Turnover is 4.55. Alfresa Holdings' value of 1.03 is 77.4% below this industry median. Based on the distribution chart, Alfresa Holdings ranks #62 out of 116 companies in the Medical Distribution industry, which is below the industry midpoint. Overall, Alfresa Holdings has a GF Score™ of 75/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Alfresa Holdings' Receivables Turnover compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Alfresa Holdings ranks #62 out of 116 companies for Receivables Turnover. This places Alfresa Holdings in the lower half of its industry. The industry median Receivables Turnover is 4.55. Alfresa Holdings' value of 1.03 is 77.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Medical Distribution company?
The median Receivables Turnover among Medical Distribution companies is 4.55, based on 116 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alfresa Holdings's current Receivables Turnover of 1.03 is 77.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Alfresa Holdings and its competitors. For the Medical Distribution industry, the median Receivables Turnover is 4.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alfresa Holdings's current Receivables Turnover is 1.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alfresa Holdings stock overvalued right now?
Based on GuruFocus' analysis, Alfresa Holdings (ALFRY) is currently considered Modestly Undervalued. The stock's GF Value™ is $16.24, compared to a current price of $13.55 — trading 16.6% below its estimated fair value. The current Receivables Turnover is 1.03 and 77.4% below the Medical Distribution industry median of 4.55. Alfresa Holdings' overall GF Score™ is 75/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Alfresa Holdings (ALFRY), the current Receivables Turnover is 1.03 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alfresa Holdings (ALFRY) Overvalued in 2026?
Based on GuruFocus' analysis, Alfresa Holdings stock appears to be undervalued.
The current stock price of $13.55 is trading 16.6% below its estimated GF Value™ of $16.24.
GuruFocus considers Alfresa Holdings to be Modestly Undervalued.
Key valuation signals for ALFRY:
Receivables Turnover: 1.03
GF Value™: $16.24 vs. price of $13.55 (16.6% below fair value)
Industry Position: 77.4% below the Medical Distribution median (#62 of 116)
No single metric tells the full story. See the ALFRY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alfresa Holdings Corp is engaged in the pharmaceutical distribution and related businesses. The company operates through four reportable segments: Wholesale business of medical drugs, Self-Medication Wholesale Business, Pharmaceutical Manufacturing Business, and Medical-Related Business. Its operations include the wholesale of ethical and over-the-counter pharmaceuticals, the manufacture and sale of pharmaceuticals, medical testing reagents, and medical equipment, as well as the operation of dispensing pharmacies.
75GF Score
Get the complete analysis for ALFRY
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ALFRY has been successfully added to your 
